Drug interactions
Empagliflozin-linagliptin + Larotrectinib
Severity: Minor
Empagliflozin-linagliptin and Larotrectinib: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Larotrectinib is a CYP3A4 substrate with weak inhibitory potential and may marginally raise linagliptin levels. A clinically meaningful change is unlikely.
What this interaction means in plain words
Empagliflozin-linagliptin and Larotrectinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Empagliflozin-linagliptin belongs to Endocrine; Larotrectinib belongs to Oncology.
Why it happens
Weak CYP3A4 inhibition by larotrectinib may slightly decrease linagliptin metabolism.
What to do
No adjustment is required. Monitor routine glycemic control.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Empagliflozin-linagliptin and Larotrectinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Empagliflozin-linagliptin
Other interactions of Larotrectinib
Frequently asked questions
Can I take Empagliflozin-linagliptin with Larotrectinib?
MediHelp rates the interaction as minor. Empagliflozin-linagliptin and Larotrectinib have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Larotrectinib is a CYP3A4 substrate with weak inhibitory potential and may marginally raise linagliptin levels. A clinically meaningful change is unlikely.
How serious is the interaction between Empagliflozin-linagliptin and Larotrectinib?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No adjustment is required. Monitor routine glycemic control.
What other medicines interact with Empagliflozin-linagliptin?
MediHelp also lists interactions of Empagliflozin-linagliptin with, for example, Fosphenytoin, Rifampin, Rifapentine. The full list is on the Empagliflozin-linagliptin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
